Oxidored-nitro domain-containing protein 1 expression is associated with the progression of hepatocellular carcinoma

Li,Deng‑Qing; Qiu,Ming; Nie,Xin‑Min; Gui,Rong; Huang,Min‑Zhu

doi:10.3892/ol.2016.4362

Oxidored-nitro domain-containing protein 1 expression is associated with the progression of hepatocellular carcinoma

Authors:
- Deng‑Qing Li
- Ming Qiu
- Xin‑Min Nie
- Rong Gui
- Min‑Zhu Huang
View Affiliations

Affiliations: Department of Laboratory Medicine, Xiangya Medical School, Central South University, Changsha, Hunan 410013, P.R. China, Clinical Laboratory Centre of The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Public Health School of Central South University, Changsha, Hunan 410078, P.R. China
Published online on: March 22, 2016 https://doi.org/10.3892/ol.2016.4362
Pages: 3003-3008
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocarcinogenesis is a stepwise process during which multiple genes are altered. Understanding the molecular mechanisms that induce hepatocarcinogenesis may improve the screening, prevention and treatment of patients with hepatocellular carcinoma (HCC). In recent years, the oxidored‑nitro domain‑containing protein 1 (NOR1) gene has been identified to have an important role in the development of HCC in vitro experiments. The current study aimed to examine the expression of NOR1 mRNA and protein expression in specimens of normal liver, hepatitis, cirrhosis and HCC, together representing the process of HCC development. Furthermore, the association between NOR1 expression and clinicopathological parameters of HCC patients was analyzed. Tissue microarrays containing the specimens of human normal liver, hepatitis, cirrhosis and HCC were purchased, and in situ hybridization and immunohistochemistry were used to detect the expression of NOR1 mRNA and protein expression, respectively. It was revealed that the positive rate of NOR1 protein and mRNA expression in the specimens of hepatitis and cirrhosis were not significantly different from that in the normal liver samples. However, the specimens of HCC exhibited an increased positive rate of NOR1 protein and mRNA expression in comparison with the normal liver samples. In addition, a higher positive rate of NOR1 protein expression was observed in HCC patients with a poor pathological differentiation grade and high tumor node metastasis (TNM) stage. In conclusion, the present study provides evidence, for the first time, of the increased expression of NOR1 in human HCC tissues, and its correlation with the pathological stage and TNM status. These findings indicate that NOR1 may be involved in the progression of HCC and it could be employed as a predictive biomarker in HCC development.

View Figures

View References

1	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
2	Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491. 2009. View Article : Google Scholar : PubMed/NCBI
3	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
4	Zhang W, Shu XO, Li H, Yang G, Cai H, Ji BT, Gao J, Gao YT, Zheng W and Xiang YB: Vitamin intake and liver cancer risk: A report from two cohort studies in China. J Natl Cancer Inst. 104:1173–1181. 2012. View Article : Google Scholar : PubMed/NCBI
5	Teo EK and Fock KM: Hepatocellular carcinoma: An Asian perspective. Dig Dis. 19:263–268. 2001. View Article : Google Scholar : PubMed/NCBI
6	Zhu AX: Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be? Oncologist. 11:790–800. 2006. View Article : Google Scholar : PubMed/NCBI
7	El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI
8	Thomas MB and Zhu AX: Hepatocellular carcinoma: The need for progress. J Clin Oncol. 23:2892–2899. 2005. View Article : Google Scholar : PubMed/NCBI
9	Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinogenesis (review). Int J Oncol. 42:1133–1138. 2013.PubMed/NCBI
10	Hagymási K and Tulassay Z: Epidemiology, risk factors and molecular pathogenesis of primary liver cancer. Orv Hetil. 149:541–548. 2008.(In Hungarian). View Article : Google Scholar : PubMed/NCBI
11	Nie X, Zhang B, Li X, Xiang J, Xiao B, Ma J, Zhou M, Zhu S, Lu H, Gui R, et al: Cloning, expression and mutation analysis of NOR1, a novel human gene down-regulated in HNE1 nasopharyngeal carcinoma cell line. J Cancer Res Clin Oncol. 129:410–414. 2003. View Article : Google Scholar : PubMed/NCBI
12	Gui R, Li D, Qi G, Suhad A and Nie X: Inhibition of Grb2-mediated activation of MAPK signal transduction suppresses NOR1/CB1954-induced cytotoxicity in the HepG2 cell line. Oncol Lett. 4:566–570. 2012.PubMed/NCBI
13	Shen CM, Nie XM and Li DQ: Screening of genes differentially expressed in HepG2 cells transfected with NOR1 gene using DNA microarray. Practical Preventive Medicine. 14:609–611. 2007.(In Chinese).
14	Gu X, Fu M, Ding Y, Ni H, Zhang W, Zhu Y, Tang X, Xiong L, Li J, Qiu L, et al: TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC. PLoS One. 9:e1061612014. View Article : Google Scholar : PubMed/NCBI
15	Friedrichs K, Gluba S, Eidtmann H and Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer. 72:3641–3647. 1993. View Article : Google Scholar : PubMed/NCBI
16	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual (7th). Springer. New York: 2010.
17	Li W, Li X, Wang W, Li X, Tan Y, Yi M, Yang J, McCarthy JB, Xiong W, Wu M, et al: NOR1 is an HSF1- and NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinoma. Carcinogenesis. 32:1305–1314. 2011. View Article : Google Scholar : PubMed/NCBI
18	Xu Z, Chen L, Leung L, Yen TS, Lee C and Chan JY: Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci USA. 102:4120–4125. 2005. View Article : Google Scholar : PubMed/NCBI
19	Dai C, Whitesell L, Rogers AB and Lindquist S: Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell. 130:1005–1018. 2007. View Article : Google Scholar : PubMed/NCBI
20	Li W, Li X, Wang W, Yi M, Zhou Y, Zheng P, Xiong W, Yang J, Peng S, McCarthy JB, et al: Tumor suppressor gene Oxidored-nitro domain-containing protein 1 regulates nasopharyngeal cancer cell autophagy, metabolism and apoptosis in vitro. Int J Biochem Cell Biol. 45:2016–2026. 2013. View Article : Google Scholar : PubMed/NCBI
21	Ouyang J, Wu M, Huang C, Cao L and Li G: Overexpression of oxidored-nitro domain containing protein 1 inhibits human nasopharyngeal carcinoma and cervical cancer cell proliferation and induces apoptosis: Involvement of mitochondrial apoptotic pathways. Oncol Rep. 29:79–86. 2013.PubMed/NCBI
22	Wang W, Li X, Zhang W, Li W, Yi M, Yang J, Zeng Z, Wanshura Colvin LE, McCarthy JB, Fan S, et al: Oxidored-nitro domain containing protein 1 (NOR1) expression suppresses slug/vimentin but not snail in nasopharyngeal carcinoma: Inhibition of EMT in vitro and in vivo in mice. Cancer Lett. 348:109–118. 2014. View Article : Google Scholar : PubMed/NCBI
23	Shan Z, Hou Q, Zhang N, Guo L, Zhang X, Ma Y and Zhou Y: Overexpression of oxidored-nitro domain containing protein 1 induces growth inhibition and apoptosis in human prostate cancer PC3 cells. Oncol Rep. 32:1939–1946. 2014.PubMed/NCBI
24	Li YJ, Wang WW and Li DQ: Effect of NOR1 Gene on Level of E-selectin in HepG2 Cells and its Mechanism. The Practical Journal of Cancer. 25:9–12. 2010.(In Chinese).
25	Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
26	Davila JA, Morgan RO, Shaib Y, McGlynn KA and El-Serag HB: Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study. Gastroenterology. 127:1372–1380. 2004. View Article : Google Scholar : PubMed/NCBI
27	Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P and El-Serag HB: Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 140:1182–1188. 2011. View Article : Google Scholar : PubMed/NCBI
28	Xiang B, Wang W, Li W, Li X, Li X and Li G: Differential expression of oxidored nitro domain containing protein 1 (NOR1), in mouse tissues and in normal and cancerous human tissues. Gene. 493:18–26. 2012. View Article : Google Scholar : PubMed/NCBI
29	Xiang B, Yi M, Wang L, Liu W, Zhang W, Ouyang J, Peng Y, Li W, Yin D, Zhou M, et al: Preparation of polyclonal antibody specific for NOR1 and detection of its expression pattern in human tissues and nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai). 41:754–762. 2009. View Article : Google Scholar : PubMed/NCBI